© 1998 by Oxford University Press
Journal Of The National Cancer Institute, Vol 90, 1468-1473, Copyright © 1998 by Oxford University Press
B Souttou, H Juhl, J Hackenbruck, M Rockseisen, HJ Klomp, D Raulais, M Vigny and A Wellstein
BACKGROUND: Growth factors produced by tumor cells are essential for tumor
expansion and may be useful in monitoring tumor progression or therapeutic
efficacy if the factors are released into the circulation. In this study,
we measured serum levels of pleiotrophin, a secreted heparin-binding growth
and angiogenesis factor, in mice bearing human tumor xenografts to
determine whether these levels reflected overall tumor burden, and we
examined the relationship between tumor expression of pleiotrophin and
serum levels of this factor in patients with cancer. METHODS: Pleiotrophin
in serum from mice and humans was measured by use of a highly sensitive
enzyme-linked immunosorbent assay. For the clinical studies, serum
specimens were obtained from 193 patients with various cancers of the
gastrointestinal tract and from 28 healthy control subjects. In a subset of
64 cancer patients, serum levels of pleiotrophin were measured at the time
of surgery, and tumor expression of this factor was detected
immunohistochemically. All P values are two-sided. RESULTS: In mice, serum
pleiotrophin levels were found to increase as a function of tumor size. In
humans, elevated serum pleiotrophin levels were found in patients with
pancreatic cancer (n = 41; P<.0001) and colon cancer (n = 65; P = .0079)
but not in patients with stomach cancer (n = 87; P =.42). A statistically
significant positive association was found between elevated levels of
pleiotrophin in serum drawn at the time of surgery and expression of this
factor by tumors (P<.0001). In both mice and humans, serum pleiotrophin
levels dropped after successful tumor removal. CONCLUSIONS: Elevated serum
pleiotrophin levels can indicate the presence of tumors expressing this
factor. Monitoring serum levels of pleiotrophin may prove useful in
determining the pharmacologic efficacy of cytotoxic or anti-pleiotrophin
therapy.
ARTICLES
Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors
Lombardi Cancer Center and Department of Pharmacology, Georgetown University, Washington, DC 20007, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Chen, R. A. Campbell, Y. Chang, M. Li, C. S. Wang, J. Li, E. Sanchez, M. Share, J. Steinberg, A. Berenson, et al. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis Blood, February 26, 2009; 113(9): 1992 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Duces, R. Karaky, D. Martel-Renoir, L. Mir, Y. Hamma-Kourbali, I. Bieche, P. Opolon, J. Delbe, J. Courty, M. Perricaudet, et al. 16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development Mol. Cancer Ther., September 1, 2008; 7(9): 2817 - 2827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Dineen, K. D. Lynn, S. E. Holloway, A. F. Miller, J. P. Sullivan, D. S. Shames, A. W. Beck, C. C. Barnett, J. B. Fleming, and R. A. Brekken Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice Cancer Res., June 1, 2008; 68(11): 4340 - 4346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chen, M. S. Gordon, R. A. Campbell, M. Li, C. S. Wang, H. J. Lee, E. Sanchez, S. J. Manyak, D. Gui, D. Shalitin, et al. Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth Blood, July 1, 2007; 110(1): 287 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Li, Y. Hu, Y. Huo, M. Liu, D. Freeman, J. Gao, X. Liu, D.-C. Wu, and H. Wu PTEN Deletion Leads to Up-regulation of a Secreted Growth Factor Pleiotrophin J. Biol. Chem., April 21, 2006; 281(16): 10663 - 10668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Boerboom, L. D. White, S. Dalle, J. Courty, and J. S. Richards Dominant-Stable {beta}-Catenin Expression Causes Cell Fate Alterations and Wnt Signaling Antagonist Expression in a Murine Granulosa Cell Tumor Model Cancer Res., February 15, 2006; 66(4): 1964 - 1973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Polykratis, P. Katsoris, J. Courty, and E. Papadimitriou Characterization of Heparin Affin Regulatory Peptide Signaling in Human Endothelial Cells J. Biol. Chem., June 10, 2005; 280(23): 22454 - 22461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Mintz, R. Sowers, K. M. Brown, S. C. Hilmer, B. Mazza, A. G. Huvos, P. A. Meyers, B. LaFleur, W. S. McDonough, M. M. Henry, et al. An Expression Signature Classifies Chemotherapy-Resistant Pediatric Osteosarcoma Cancer Res., March 1, 2005; 65(5): 1748 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aigner, P. Brachmann, J. Beyer, R. Jager, D. Raulais, M. Vigny, A. Neubauer, A. Heidenreich, S. Weinknecht, F. Czubayko, et al. Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients Ann. Onc., October 1, 2003; 14(10): 1525 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, S. Oparil, J. A. Feng, P. Li, G. Perry, L. B. Chen, M. Dai, S. W.M. John, and Y.-F. Chen Effects of Pressure Overload on Extracellular Matrix Expression in the Heart of the Atrial Natriuretic Peptide-Null Mouse Hypertension, July 1, 2003; 42(1): 88 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Stoica, A. Kuo, C. Powers, E. T. Bowden, E. B. Sale, A. T. Riegel, and A. Wellstein Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types J. Biol. Chem., September 20, 2002; 277(39): 35990 - 35998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bernard-Pierrot, J. Delbe, V. Rouet, M. Vigny, M.-E. Kerros, D. Caruelle, D. Raulais, D. Barritault, J. Courty, and P. E. Milhiet Dominant Negative Effectors of Heparin Affin Regulatory Peptide (HARP) Angiogenic and Transforming Activities J. Biol. Chem., August 23, 2002; 277(35): 32071 - 32077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Powers, A. Aigner, G. E. Stoica, K. McDonnell, and A. Wellstein Pleiotrophin Signaling through Anaplastic Lymphoma Kinase Is Rate-limiting for Glioblastoma Growth J. Biol. Chem., April 12, 2002; 277(16): 14153 - 14158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Klomp, O. Zernial, S. Flachmann, A. Wellstein, and H. Juhl Significance of the Expression of the Growth Factor Pleiotrophin in Pancreatic Cancer Patients Clin. Cancer Res., March 1, 2002; 8(3): 823 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Weber, H.-J. Klomp, F. Czubayko, A. Wellstein, and H. Juhl Pleiotrophin Can Be Rate-limiting for Pancreatic Cancer Cell Growth Cancer Res., September 1, 2000; 60(18): 5284 - 5288. [Abstract] [Full Text]
|
|
|
|
|
|
G. E. Stoica, A. Kuo, A. Aigner, I. Sunitha, B. Souttou, C. Malerczyk, D. J. Caughey, D. Wen, A. Karavanov, A. T. Riegel, et al. Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin J. Biol. Chem., May 11, 2001; 276(20): 16772 - 16779. [Abstract] [Full Text] [PDF]
|
|